{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Nucleocytoplasmic Compartment-Selective PRMT Inhibition",
"mechanism": "Design PRMT inhibitors with subcellular compartmental targeting to modulate TDP-43 methylation in the nucleus while sparing cytoplasmic PRMT activity that maintains systemic ADMA homeostasis.",
"target_gene": "TARDBP/TDP-43",
"confidence_score": 0.55,
"novelty_score": 0.85,
"feasibility_score": 0.35,
"impact_score": 0.80,
"composite_score": 0.64,
"testable_prediction": "Compare methylation status of nuclear vs cytoplasmic TDP-43 in patient-derived neurons before and after treatment with compartment-constrained PRMT inhibitors at varying doses.",
"skeptic_concern": "Current PRMT inhibitor chemistry lacks subcellular specificity; achieving selective nuclear compartmentalization requires novel drug delivery approaches not yet demonstrated in vivo."
},
{
"rank": 2,
"title": "ADMA-Guided Adaptive PRMT Modulation",
"mechanism": "Use plasma/CSF ADMA concentration as a real-time feedback biomarker to titrate PRMT inhibitor dosing, maintaining methylation within a physiological goldilocks zone (ADMA 0.4-0.6 μM).",
"target_gene": "PRMT1/PRMTs",
"confidence_score": 0.50,
"novelty_score": 0.65,
"feasibility_score": 0.45,
"impact_score": 0.75,
"composite_score": 0.59,
"testable_prediction": "Conduct a dose-escalation trial measuring simultaneous plasma ADMA, CSF ADMA, and neuronal TDP-43 methylation status to validate correlation between systemic biomarker and neuronal substrate status.",
"skeptic_concern": "Biomarker-substrate disconnect—systemic ADMA does not reliably reflect neuronal PRMT activity at critical substrates like TDP-43 due to body-wide PRMT distribution."
},
{
"rank": 3,
"title": "Splicing-Activity-Coupled TDP-43 Methylation Monitoring",
"mechanism": "Measure downstream splicing activity of TDP-43 as a functional readout of its methylation status, using splicing efficiency of known TDP-43 targets as a direct neuronal endpoint for dose titration.",
"target_gene": "TARDBP/TDP-43",
"confidence_score": 0.60,
"novelty_score": 0.50,
"feasibility_score": 0.55,
"impact_score": 0.65,
"composite_score": 0.58,
"testable_prediction": "Establish dose-response curves for PRMT modulators by measuring both TDP-43 methylation (by mass spectrometry) and splicing efficiency of downstream targets (e.g., HDAC6, STM1) in patient neurons.",
"skeptic_concern": "Splicing changes may reflect compensatory responses rather than direct methylation effects, and baseline splicing signatures vary between patients complicating interpretation."
}
],
"consensus_points": [
"The methylation dosing paradox is a genuine barrier to clinical translation, with both hypo- and hypermethylation causing harm in neurodegeneration",
"Plasma ADMA elevation in AD patients is real but its mechanistic link to neuronal TDP-43 methylation requires validation",
"Personalized/adaptive dosing approaches are necessary given the narrow therapeutic window"
],
"dissent_points": [
"Expert rates compartment-selective approaches as highest potential while skeptic notes no current chemistry achieves subcellular targeting; debate over whether to invest in novel delivery vs biomarker validation remains unresolved"
],
"debate_summary": "The debate established that addressing the methylation dosing paradox requires either better biomarkers connecting systemic measurements to neuronal substrates (Hypothesis 1) or fundamentally novel approaches achieving subcellular compartment selectivity (Hypothesis 2). The ADMA-guided approach offers near-term feasibility via FDA-cleared assays but suffers from a mechanistic disconnect between systemic ADMA and neuronal TDP-43 methylation. Compartment-selective strategies could resolve the paradox but require substantial chemistry innovation. A functional splicing readout approach offers an intermediate path that directly measures TDP-43 activity without requiring biomarker-substrate correlation validation."
}